|Publication number||US20050261667 A1|
|Application number||US 11/191,053|
|Publication date||Nov 24, 2005|
|Filing date||Jul 28, 2005|
|Priority date||Dec 21, 2000|
|Also published as||CA2431421A1, CA2431421C, DE60139573D1, EP1351646A2, EP1351646B1, US6616626, US6939322, US20020082546, US20040019311, WO2002049695A2, WO2002049695A3, WO2002049695A9|
|Publication number||11191053, 191053, US 2005/0261667 A1, US 2005/261667 A1, US 20050261667 A1, US 20050261667A1, US 2005261667 A1, US 2005261667A1, US-A1-20050261667, US-A1-2005261667, US2005/0261667A1, US2005/261667A1, US20050261667 A1, US20050261667A1, US2005261667 A1, US2005261667A1|
|Inventors||Justin Crank, Scott Larson, Timothy Mickley|
|Original Assignee||Boston Scientific Scimed, Inc.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (50), Referenced by (5), Classifications (25)|
|External Links: USPTO, USPTO Assignment, Espacenet|
The present application is a continuation of U.S. application Ser. No. 10/621,378, which was filed on Jul. 18, 2003, was entitled Infusion Devices and Method and is now U.S. Pat. No. ______. The '378 application is itself a continuation of U.S. Pat. No. 6,616,626, which was filed on Dec. 21, 2000 and shares the same name.
The present invention is related generally to medical devices. More specifically, the present invention is related to devices and methods associated with delivery of genes or therapeutic substances.
A number of techniques are available for treating heart disease and diseases of other organs percutaneously. Examples of such techniques include delivery of genes and therapeutic substances, including the delivery of genes and therapeutic substances for percutaneous myocardial revascularization (PMR). This procedure is performed to increase blood perfusion through the myocardium of a patient. For example, in some patients, the number of lesions in coronary vessels is so great or the location so remote in the patient vasculature that restoring blood flow to the heart muscle is difficult. Percutaneous myocardial revascularization (PMR) has been developed as an alternative to techniques which are directed at bypassing or removing lesions. PMR is performed by boring holes directly into the myocardium of the heart. Positive results have been demonstrated in some human patients receiving PMR treatments. These results are believed to be caused in part by blood flowing from within a heart chamber through patent holes formed by PMR to the myocardial tissue. Suitable PMR holes have been proposed to be burned by laser, cut by mechanical means, and burned by radio frequency devices. Increased blood flow to the myocardium is also believed to be caused in part by the healing response to wound formation, specifically, the formation of new blood vessels in response to the newly created wound.
Several aspects of PMR procedures could be improved upon. One area for improvement is in the preparation of PMR injection catheters for use by the treating physician. In particular, at present, the PMR device maybe flushed with a drug to prime the distal needle by flushing the drug through the needle and into a container. This preparation can be awkward and may leave a container of biologically active material which may require further processing. Another aspect which may be farther optimized lies in the attachment of the needle to the distal region of the PMR catheter tube. In particular, forces may act upon the needle during both the advancement and retraction of the needle within the heart wall, urging the needle undesirably both into and out of the tube. Improved methods of securing the needle to the tube would be desirable.
During a PMR treatment, a physician may be attempting to treat a three-dimensional space using a catheter having a distal bend. In particular, the physician may be attempting to treat the heart chamber side, anterior, and posterior wall regions. This may presently be difficult to visualize under fluoroscopy as current marking systems for shafts may make interpretation of the catheter distal region orientation somewhat ambiguous. The heart chamber wall thickness can vary depending on the chamber and wall region being treated. In particular, the left ventricle wall is thinner in the posterior region relative to the anterior region. Improved devices for variable depth, yet controlled penetration of the heart walls, would be advantageous. As multiple sites of the heart chamber wall are penetrated, a system for tracking the treated versus untreated regions would also be desirable.
The present invention includes improved devices and methods for performing PMR procedures. One device allows for improved preparation of PMR catheters used to inject a drug or therapeutic substance into the heart wall. One such device includes a PMR device distal region or hood disposed within the neck of a vial for receiving the drug. The vial can be used to receive the drug while the drug is being flushed through the PMR device and needle to prepare the PMR device for use. One vial has a neck and shoulder region for receiving and retaining the distal region of a PMR injection device. A no-leak gasket defines one wall of an inner cavity within one such vial.
The vial is preferably formed of a transparent or translucent material for observing the injection of the drug into the vial. In one embodiment, the vial cavity includes a drug-neutralizing agent. The agent allows the drug to be neutralized after receiving the drug. A neutralizing agent can provide improved safety, should the integrity of the vial be breached. The drug-neutralizing vial allows a biologically active drug to be flushed through the catheter with the vial being disposed of in a normal waste stream such as a wastebasket, rather than requiring special handling.
One set of devices provides improved needle attachment to drug delivery tubes. One improved drug delivery tube has an outer tube defining a lumen therein. A needle may be disposed within the distal end of the tube. The needle can have a distal, sharp tube region for insertion into the heart wall, as a well as a wider, more proximal region having outward protrusions for engaging or biting into the drug delivery tube inner wall. One device has a wide flange for abutting the drug delivery tube distal end, thereby limiting the proximal travel of the needle into the drug delivery tube lumen. One drug delivery tube also has a bonding hole which can be used to inject an adhesive to further secure the needle within the drug delivery tube distal region. The improved securing of the needle to the drug delivery tube can act to prevent the needle from being distally pulled from the tube.
During insertion of the needle into the heart wall, forces can act to urge the needle into the tube. Upon retraction of the needle from the heart wall, forces may act to pull the needle distally from the tube. Both the outward protrusions, the flange, and the added adhesive can act to better secure the needle to the drug delivery tube. One embodiment includes outward barbs biting into the drug delivery tube, while another embodiment uses a series of helically disposed screw threads to engage the tube wall. A preferred embodiment uses outward protruding elements which engage the inner wall, while another embodiment uses inwardly protruding elements engaging the outer wall of the tube distal region.
Another aspect of the invention provides improved visualization of the catheter shaft orientation under fluoroscopy. One embodiment utilizes asymmetrically disposed radiopaque markers on the shaft distal region to enable the treating physician to determine whether the catheter distal region is pointed at right angles to the treating physician or is pointed toward or away from the treating physician. One embodiment has the radiopaque marker being asymmetrically distributed with respect to a plane bisecting a longitudinal axis of the catheter tube distal region. Another embodiment further includes the radiopaque marker being asymmetrically distributed with respect to length over the catheter distal region. One marker includes an annular ring portion and a straight leg portion lying along the length of one side of the tube. Yet another embodiment includes an annular shell or ring portion and an annular arc leg portion extending along a length from the annular shell or ring portion. The radiopaque markers may be disposed on either the proximal or the distal side of any bend in the catheter shaft. A preferred use of the radiopaque marker band is on a guide catheter used to guide a PMR therapeutic tip to the heart wall.
In yet another aspect of the invention, radiopaque marker segments are asymmetrically distributed such that the rotation of the tube relative to the treating physician may be determined under fluoroscopy. One embodiment uses opposing annular shells on opposing sides of a tube where the annular shells are shifted longitudinally relative to each other. The asymmetrically disposed shells are thus asymmetric both with respect to a plane bisecting a longitudinal central access and with respect to a plane transversely bisecting a catheter shaft.
In still another aspect of the invention, marker bands are provided a distance apart which approximates the desired inter-treatment site spacing along the heart wall. A method can be performed using this aspect of the invention, whereby a therapeutic substance is delivered at treatment sites which are observed under fluoroscopy to be spaced apart approximately the distance between marker bands. Any distortion or magnification of the distances between marker bands will approximately be matched by distortions between treatment sites.
The present invention also includes a PMR device for allowing precise, variable depth needle penetration of the heart wall. One device includes at least one inner stop affixed to a rotatable inner needle. The device also can have one or more stops disposed inwardly from an outer tube, the outer tube having the inner needle rotatably disposed within. The inner needle can be longitudinally advanced until the inner stop abuts an outer stop, thereby inhibiting further distal movement of the inner needle. If greater penetration is desired, the inner shaft can be rotated, thereby swinging the inner stop clear of the first encountered outer stop, allowing the inner stop to proceed further distally until a subsequent outer stop is encountered. This aspect of the invention allows a single device to be used, yet provides multiple, preset, precise penetration depths. This may be of particular use where the thickness of the heart wall varies over different regions of the heart chamber wall.
Yet another aspect of the invention provides for injection of drug and contrast media into the heart wall. Injection of contrast media near the injection site of a drug allows the treating physician to visualize under fluoroscopy which areas of the heart wall have been treated and which have not yet been treated. One device provides a contrast media injection needle disposed side-by-side with a drug delivery needle. One embodiment allows the two side-by-side needles to be retracted and advanced together. The needles can be distally straight, arcuate, or one arcuate and one straight. Another embodiment provides a drug and contrast media injection device having a pair of needles, one being coaxially disposed within the other. The innermost needle can be used to inject drug deep into the heart tissue, while the more outer, coaxially disposed needle may be used to inject contrast media to the heart wall, thereby marking the site of treatment. One embodiment utilizes a sharp, cutting end to inject contrast media. Another embodiment uses a less sharp, less cutting end, for injecting a contrast media into the heart wall tissue using pressure, rather than cutting.
Drug receiving vial 32 includes a wall 38, which is preferably formed of a transparent or translucent material, allowing both an expelled drug and catheter needle to be viewed through the vial wall. Vial 32 includes a cavity 34 having a drug-neutralizing agent 36 disposed within cavity 34. Vial 32 includes a neck region 58 for receiving catheter distal portion 54. In one embodiment, vial 32 further includes a shoulder or contour region 56 for engaging catheter distal hood 48. In some embodiments, vial shoulder 56 and catheter hood 48 are cooperatively sized such that shoulder 56 engages hood 48 even when hood 48 is in a non-expanded state. Hood 48 is preferably sufficiently compliant so as to allow retraction of hood 48 through vial neck region 58 after preparing the catheter. Vial shoulder 56 can also flex to contain hood 48.
In use, drug delivery catheter preparing system 30 can be provided substantially as illustrated in
Catheter 42 can be used to inject various drugs or other therapeutic substances into the myocardium. Examples of therapeutic substances include small molecular drugs, proteins, genes and cells which could promote angiogenesis, protect tissues (i.e., cardiac protection), or promote tissue regeneration. Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth Factors (FGFs) are believed suitable for use with the present invention. Carriers for the therapeutic agents of the present invention can include polymers, angiopoietins, biodegradable and biostable hydrogels, and dissoluble polymers. Adhesives suitable for binding the present invention include fibrin glues and cyanoacrylates which may also be included with the therapeutic substance to improve the desired response. Drug injection catheters referred to in the remainder of the present patent application, and drugs similarly referenced, may include the injection and use of the aforementioned therapeutic substances.
Catheter 42, as well as subsequently referenced drug injection catheters or myocardial revascularization catheters, can include catheters such as those described in co-pending U.S. patent application Ser. No. 09/271,045, filed Mar. 17, 1999, entitled TRANSMYOCARDIAL REVASCULARIZATION CATHETER AND ASSEMBLY; and U.S. patent application Ser. No. 09/184,220, filed Nov. 2, 1998, entitled PERCUTANEOUS MYOCARDIAL REVASCULARIZATION GROWTH FACTOR MEDIUMS AND METHOD, herein incorporated by reference. In particular, guide catheters described according to the present invention may be used to guide these previously referenced devices, and others, to target sites in the myocardium.
As can be seen in
In one use, drug delivery catheter 60 can be advanced through the vasculature and into a heart chamber wall. After injection of a drug through drug lumen 66, drug delivery catheter 60 can be retracted, thereby retracting needle distal end 84. In a situation where the heart wall grips needle distal tube portion 83, barbs or protrusions 86 can serve to resist the distally directed force attempting to retain needle 78.
Another drug delivery catheter 100 is illustrated in
As can be seen from inspection of
In one embodiment, first lumen 416 is used to inject radiopaque fluid, while second lumen 418 is used to inject a drug as part of the PMR procedure. In another embodiment, first lumen 416 is used to inject a drug, while second lumen 418 is used to inject a radiopaque material. In this latter embodiment, the straight needle 428 can be used to inject radiopaque material at the center of a circular pattern formed by the repeated injection of a drug through first needle 426. Injection of the radiopaque fluid allows the treating physician to visualize under fluoroscopy which areas of the heart wall have already been treated with the drug.
In one embodiment, first lumen 454 is used to inject a drug through needle 462. In this embodiment, second or intermediate lumen 458 is used to inject a radiopaque dye through second or intermediate needle 463. In the embodiment illustrated in
In the illustrated embodiment, tube 490 is fixed relative to outer tube 484, while inner tube 498 can be slidably disposed with respect to tube 490. In this embodiment, radiopaque contrast media may be injected at approximately the same site as a drug delivered in a PMR procedure. In one embodiment, a drug is injected through inner tip 502, while a contrast media is injected through tip 494. In another embodiment, contrast media is injected through tip 502, while a drug or other therapeutic substance is delivered through the outer distal tip 494. In the embodiment illustrated in
Numerous advantages of the invention covered by this document have been set forth in the foregoing description. It will be understood, however, that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of parts without exceeding the scope of the invention. The invention's scope is, of course, defined in the language in which the appended claims are expressed.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4279252 *||Aug 24, 1979||Jul 21, 1981||Martin Michael T||X-ray scaling catheter|
|US4434822 *||Oct 27, 1981||Mar 6, 1984||Baxter Travenol Laboratories, Inc.||System for the sterile mixing of materials|
|US4760131 *||Jun 23, 1986||Jul 26, 1988||Collagen Corporation||Wound-healing composition|
|US4790311 *||Jan 20, 1987||Dec 13, 1988||Ruiz Oscar F||Radio frequency angioplasty catheter system|
|US4896671 *||Aug 1, 1988||Jan 30, 1990||C. R. Bard, Inc.||Catheter with contoured ablation electrode|
|US5047026 *||Jul 2, 1990||Sep 10, 1991||Everest Medical Corporation||Electrosurgical implement for tunneling through tissue|
|US5093877 *||Oct 30, 1990||Mar 3, 1992||Advanced Cardiovascular Systems||Optical fiber lasing apparatus lens|
|US5203777 *||Mar 19, 1992||Apr 20, 1993||Lee Peter Y||Radiopaque marker system for a tubular device|
|US5261889 *||Nov 24, 1992||Nov 16, 1993||Boston Scientific Corporation||Injection therapy catheter|
|US5287861 *||Oct 30, 1992||Feb 22, 1994||Wilk Peter J||Coronary artery by-pass method and associated catheter|
|US5358485 *||Aug 16, 1993||Oct 25, 1994||Schneider (Usa) Inc.||Cutter for atherectomy catheter|
|US5364393 *||Dec 30, 1993||Nov 15, 1994||Heart Technology, Inc.||Tissue dissipative recanalization catheter|
|US5370675 *||Feb 2, 1993||Dec 6, 1994||Vidamed, Inc.||Medical probe device and method|
|US5380316 *||Jun 16, 1993||Jan 10, 1995||Advanced Cardiovascular Systems, Inc.||Method for intra-operative myocardial device revascularization|
|US5389096 *||Feb 25, 1993||Feb 14, 1995||Advanced Cardiovascular Systems||System and method for percutaneous myocardial revascularization|
|US5403311 *||Mar 29, 1993||Apr 4, 1995||Boston Scientific Corporation||Electro-coagulation and ablation and other electrotherapeutic treatments of body tissue|
|US5429256 *||Jan 24, 1994||Jul 4, 1995||Kestenbaum; Alan D.||Drug withdrawal system for container|
|US5431649 *||Aug 27, 1993||Jul 11, 1995||Medtronic, Inc.||Method and apparatus for R-F ablation|
|US5522815 *||Aug 9, 1994||Jun 4, 1996||Durgin, Jr.; Russell F.||Integrated catheter for diverse in situ tissue therapy|
|US5551427 *||Feb 13, 1995||Sep 3, 1996||Altman; Peter A.||Implantable device for the effective elimination of cardiac arrhythmogenic sites|
|US5569462 *||Mar 31, 1995||Oct 29, 1996||Baxter International Inc.||Methods for enhancing vascularization of implant devices|
|US5591159 *||Nov 9, 1994||Jan 7, 1997||Taheri; Syde A.||Transcavitary myocardial perfusion apparatus|
|US5593405 *||Jan 9, 1995||Jan 14, 1997||Osypka; Peter||Fiber optic endoscope|
|US5607405 *||May 9, 1994||Mar 4, 1997||Decker; Rand A.||Surgical insertion device and method|
|US5620414 *||Apr 8, 1994||Apr 15, 1997||Campbell, Jr.; Robert M.||Apparatus and method for effecting surgical incision through use of a fluid jet|
|US5672174 *||Jan 16, 1996||Sep 30, 1997||Rita Medical Systems, Inc.||Multiple antenna ablation apparatus and method|
|US5674192 *||Jul 23, 1993||Oct 7, 1997||Boston Scientific Corporation||Drug delivery|
|US5681308 *||Nov 28, 1994||Oct 28, 1997||Stuart D. Edwards||Ablation apparatus for cardiac chambers|
|US5683366 *||Nov 22, 1995||Nov 4, 1997||Arthrocare Corporation||System and method for electrosurgical tissue canalization|
|US5697882 *||Nov 22, 1995||Dec 16, 1997||Arthrocare Corporation||System and method for electrosurgical cutting and ablation|
|US5700259 *||Oct 10, 1995||Dec 23, 1997||Plc Medical Systems, Inc.||Thoracoscopic transmyocardial revascularization handpiece assembly|
|US5713894 *||Feb 27, 1996||Feb 3, 1998||Murphy-Chutorian; Douglas||Combined mechanical/optical system for transmyocardial revascularization|
|US5725521 *||Mar 29, 1996||Mar 10, 1998||Eclipse Surgical Technologies, Inc.||Depth stop apparatus and method for laser-assisted transmyocardial revascularization and other surgical applications|
|US5725523 *||Mar 29, 1996||Mar 10, 1998||Mueller; Richard L.||Lateral-and posterior-aspect method and apparatus for laser-assisted transmyocardial revascularization and other surgical applications|
|US5810836 *||Nov 7, 1996||Sep 22, 1998||Myocardial Stents, Inc.||Device and method for trans myocardial revascularization (TMR)|
|US5871495 *||Sep 13, 1996||Feb 16, 1999||Eclipse Surgical Technologies, Inc.||Method and apparatus for mechanical transmyocardial revascularization of the heart|
|US5905594 *||Sep 10, 1996||May 18, 1999||W. L. Gore & Associates, Inc.||Light reflectant surface in a recessed cavity substantially surrounding a compact fluorescent lamp|
|US6036682 *||Dec 2, 1997||Mar 14, 2000||Scimed Life Systems, Inc.||Catheter having a plurality of integral radiopaque bands|
|US6042581 *||Nov 8, 1996||Mar 28, 2000||Thomas J. Fogarty||Transvascular TMR device and method|
|US6045565 *||Nov 2, 1998||Apr 4, 2000||Scimed Life Systems, Inc.||Percutaneous myocardial revascularization growth factor mediums and method|
|US6053911 *||Mar 18, 1997||Apr 25, 2000||Thomas J. Fogarty||Transvascular TMR device and method|
|US6053924 *||Apr 29, 1999||Apr 25, 2000||Hussein; Hany||Device and method for trans myocardial revascularization|
|US6056742 *||May 6, 1997||May 2, 2000||Eclipse Surgical Technologies, Inc.||Revascularization with laser outputs|
|US6056743 *||Mar 5, 1998||May 2, 2000||Scimed Life Systems, Inc.||Percutaneous myocardial revascularization device and method|
|US6217554 *||Feb 12, 1999||Apr 17, 2001||Pharmaspec Corporation||Methods and apparatus for delivering substances into extravascular tissue|
|US6285903 *||Jun 30, 1998||Sep 4, 2001||Eclipse Surgical Technologies, Inc.||Intracorporeal device with radiopaque marker|
|US6464693 *||Mar 6, 2000||Oct 15, 2002||Plc Medical Systems, Inc.||Myocardial revascularization|
|US6544231 *||May 22, 2000||Apr 8, 2003||Medcanica, Inc.||Catch, stop and marker assembly for a medical instrument and medical instrument incorporating the same|
|US6613017 *||Aug 8, 2000||Sep 2, 2003||Scimed Life Systems, Inc.||Controlled depth injection device and method|
|US6616626 *||Dec 21, 2000||Sep 9, 2003||Scimed Life Systems, Inc.||Infusion devices and method|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US7156872 *||Mar 27, 2003||Jan 2, 2007||Ernst Peter Strecker||Implantable valve system|
|US8114031||Jul 26, 2006||Feb 14, 2012||Johan Willem Pieter Marsman||Facilitation of antegrade insertion of a guidewire into the superficial femoral artery|
|US8292873||Aug 7, 2008||Oct 23, 2012||Boston Scientific Scimed, Inc.||Catheter devices for myocardial injections or other uses|
|US8353881 *||Dec 28, 2005||Jan 15, 2013||Abbott Diabetes Care Inc.||Infusion sets for the delivery of a therapeutic substance to a patient|
|US8900216||Nov 18, 2011||Dec 2, 2014||Johan Willem Pieter Marsman||Facilitation of antegrade insertion of a guidewire into the superficial femoral artery|
|International Classification||A61J1/14, A61M5/46, A61M25/06, A61M25/01, A61J1/00, A61M25/00, A61M25/098|
|Cooperative Classification||A61M25/0662, A61J1/1406, A61M5/46, A61M25/0074, A61M2210/125, A61M2205/19, A61M25/0068, A61M2025/0091, A61M2025/0085, A61M2025/0086, A61M25/0084, A61M2025/0081, A61M25/0108, A61M2025/0008|
|European Classification||A61M25/00T40A, A61M25/00T10, A61M25/01C1|